CHMP re­vers­es course on ner­a­tinib, hand­ing Puma an un­ex­pect­ed win on Eu­ro­pean mar­ket­ing vote — shares soar

Puma Biotech­nol­o­gy $PBYI CEO Alan Auer­bach just beat some heavy odds weigh­ing against ner­a­tinib.

Af­ter ap­peal­ing a neg­a­tive opin­ion adopt­ed by the Com­mit­tee for Med­i­c­i­nal …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER